Authors’ reply to Nandi
Author:
Affiliation:
1. Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, Maharashtra, India
Publisher
Medknow
Subject
Cancer Research,Oncology (nursing),Drug Guides,Oncology
Reference6 articles.
1. Erdafitinib can combat FGFR-mediated abnormal signaling in cancer;Nandi;Cancer Res Stat Treat,2023
2. Erdafitinib for tumors with FGFR3 mutation:A promising targeted therapy;Kaur;Cancer Res Stat Treat,2023
3. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor;Perera;Mol Cancer Ther,2017
4. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma:Where do we stand;D'Angelo;Expert Rev Clin Pharmacol,2020
5. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment;Liu;Cell Prolif,2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3